News Image

Which stocks are experiencing notable movement on Wednesday?

By Mill Chart

Last update: Apr 17, 2024

Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.

Gainers

TickerChangeComment
SBFM6.0K%Positive market sentiment drove SUNSHINE BIOPHARMA INC's (NASDAQ:SBFM) stock price up by 6.0K% to $3.95 during Wednesday's session. In the last month the share price increased with 27.1%.
INVO278.0%INVO BIOSCIENCE INC (NASDAQ:INVO) rose 278.0% to $2.87 during Wednesday's after hours session. The stock is trading 25.49% lower than a month ago.
EDBL81.54%Investors celebrated as EDIBLE GARDEN AG INC (NASDAQ:EDBL) experienced a 81.54% rise in its shares, closing at $8.26 during Wednesday's session. A press release (Edible Garden Reports Preliminary First Quarter Year-Over-Year Increase in Produce Revenues of 40%; Cut Herb Revenue Increased More Than 200% for the Same Period) was released earlier today.
SPEC75.08%SPECTAIRE HOLDINGS INC (NASDAQ:SPEC) experienced a significant 75.08% increase, reaching $1.4 during Wednesday's session. A press release (Spectaire Announces Strategic Distribution Partnership with a Fortune 1000 Energy Company) was released earlier today.
BBA.W40.97%BIGBEAR.AI HOLDINGS -CW28 (NYSE:BBA.W) witnessed a notable 40.97% uptick in its shares, reaching $0.31 during Wednesday's session. Shareholders saw the stock price going 45.43% lower in the past month.
VNDA37.9%VANDA PHARMACEUTICALS INC's (NASDAQ:VNDA) shares rose 37.9% to $5.58. In the last year the share price dropped with 36.22%.
VIRX30.86%In an impressive move, VIRACTA THERAPEUTICS INC's (NASDAQ:VIRX) shares recorded a 30.86% increase, closing at $0.94 during Wednesday's session. In the last month the stock lost 27.8%.
GRTX27.71%GALERA THERAPEUTICS INC's (NASDAQ:GRTX) stock price displayed strong growth, advancing 27.71% and reaching $0.22 during Wednesday's session. Shareholders saw the stock price going 29.84% lower in the past month.
SINT24.02%SINTX TECHNOLOGIES INC (NASDAQ:SINT) experienced a significant 24.02% increase, reaching $0.03 during Wednesday's session. Shareholders saw the stock price going 82.01% lower in the past month.
BCAN22.73%Exciting news for BYND CANNASOFT ENTERPRISES (NASDAQ:BCAN) as its stock price surged 22.73% to $1.08 during Wednesday's session. In the last month the stock lost 80.44%.

For the full top gainers list go to our top gainers page.

Top losers

TickerChangeComment
IZM-86.46%During Wednesday's session, ICZOOM GROUP INC -CLASS A's (NASDAQ:IZM) shares took a tumble, falling 86.46% to $6.91. In the last month the stock gained 461.0%.
DARE-41.56%DARE BIOSCIENCE INC's (NASDAQ:DARE) shares fell 41.56% to $0.28 during Wednesday's session. The stock is trading 56.42% higher than 3 months ago.
LGVN-40.51%LONGEVERON INC-A (NASDAQ:LGVN) encountered a 40.51% decrease in its shares, reaching $2.1 during Wednesday's session. In the last 3 months the share price dropped with 62.84%.
TPET-38.55%TRIO PETROLEUM CORP's (NYSEARCA:TPET) shares fell 38.55% to $0.3 during Wednesday's session. In the last month the stock gained 344.0%.
TMQ-37.32%There was a notable decline in TRILOGY METALS INC's (NYSEARCA:TMQ) shares, as they dropped 37.32% to $0.32 during Wednesday's session.
SXTC-25.31%Investors witnessed a 25.31% decrease in CHINA SXT PHARMACEUTICALS IN's (NASDAQ:SXTC) stock price, which closed at $1.21 during Wednesday's session. The stock is trading 42.76% lower than 6 months ago.
ISUN-23.86%During Wednesday's session, ISUN INC's (NASDAQ:ISUN) shares took a tumble, falling 23.86% to $0.16. In the last year the share price dropped with 68.65%.
HUBC-22.04%There was a notable decline in HUB CYBER SECURITY LTD's (NASDAQ:HUBC) shares, as they dropped 22.04% to $1.45 during Wednesday's session. In the last month the stock gained 82.35%.
SAGE-21.24%There was a notable decline in SAGE THERAPEUTICS INC's (NASDAQ:SAGE) shares, as they dropped 21.24% to $12.31 during Wednesday's session. Earlier today the company had a press release: Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease.
OTRK-20.2%There was a downturn in ONTRAK INC's (NASDAQ:OTRK) shares, as they experienced a 20.2% decline, closing at $0.37 during Wednesday's session. A press release (Ontrak Announces 2023 Fourth Quarter and Year End Financial Results) was released yesterday.

Our top losers page will show you the full list.

Back

SAGE THERAPEUTICS INC

NASDAQ:SAGE (5/14/2024, 10:29:57 AM)

12.15

-0.02 (-0.16%)

SAGE News

News Image4 days ago - Market News VideoSage Therapeutics Ic Becomes Oversold (SAGE)
News Image7 days ago - Sage TherapeuticsSage Therapeutics to Participate in Upcoming May Investor Conferences
News Image8 days ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such...

News Image16 days ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such...

News Image19 days ago - InvestorPlaceSAGE Stock Earnings: Sage Therapeutics Misses EPS, Beats Revenue for Q1 2024

SAGE stock results show that Sage Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

News Image19 days ago - Sage Therapeutics, Inc.Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
News Imagea month ago - Yahoo FinanceNeurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data

Wednesday, Sage Therapeutics Inc (NASDAQ:SAGE) announced topline results from the PRECEDENT Phase 2 study of dalzanemdor (SAGE-718) in people with mild cognitive impairment in Parkinson’s Disease. The PRECEDENT Study did not meet its primary endpoint of demonstrating a statistically significant difference from baseline in participants treated with once-daily dalzanemdor versus placebo on the Wechsler Adult Intelligence Scale Fourth Edition-IV (WAIS-IV) Coding Test score at Day 42. WAIS-IV is the

News Imagea month ago - Investor's Business DailySage Stock Collapses To Record Low After Parkinson's Drug Misses Its Mark

Safe Therapeutics emphasized it's still testing the same drug in patients with Alzheimer's and Huntington's diseases.

SAGE Links
Follow us for more